Research phase | Screening and randomization | Treatment period | ||
---|---|---|---|---|
Interview | 1 | 2 | 3 | 4 |
Research date | − 7–0 | 28 ± 2 | 56 ± 4 | 84 ± 6 |
Baseline information | ||||
Informed consent | ● | |||
General information | ● | |||
History | ● | |||
Physical examination | ● | ● | ● | ● |
Treatment | ||||
Inclusion/exclusion criteria | ● | |||
Combined medication | ● | ● | ● | ● |
Compliance | ● | ● | ● | |
Completion of research | ● | |||
Inclusion/exclusion criteria | ||||
PSG | ● | |||
Echocardiography | ● | |||
Security index | ||||
Blood routine | ● | ● | ||
Urine routine | ● | ● | ||
Blood biochemical | ● | ● | ||
Electrocardiogram | ● | ● | ||
Adverse event assessment | ● | ● | ● | |
Outcome | ||||
AHI | ● | ● | ||
Epworth Somnolence Scale (ESS) | ● | ● | ● | ● |
Echocardiography | ● | ● | ||
NT-proBNP | ● | ● | ||
Quality of life as measured by the Minnesota Living with Heart Failure Questionnaire | ● | ● | ● | ● |
EQ—5D—3L | ||||
LSpO2 | ● | ● | ||
Inflammatory factors | ● | ● |